ZimCal disturbed by Medallion Financial’s second quarter results
20. August 2024 15:31 ET
|
ZimCal Asset Management LLC
2Q24 results show worrying trends that must be addressed immediately.Core charge-offs (YoY), ROAA, ROAE and holding company cash-burn trended poorly.Quarterly earnings, ROAA and core ROAA (Ex. Taxi...
FCM Calls for Socially Responsible Investors to Vote for Change at MindMed
09. Juni 2023 16:17 ET
|
Concerned Shareholders of Company MindMed
Believes Socially Responsible Investment Principles Support FCM’s Plan to Bring MM-120 To the Market in 2026 to Benefit Millions with Mental Health Disorders FCM Directors Will Put in Place Strict...
ISS Appears to Rely on MindMed's False and Misleading Statements to Justify the Company's Abysmal Performance; Seemingly Ignores MindMed's Apparent Disregard of Patient Safety
05. Juni 2023 06:19 ET
|
Concerned Shareholders of Company MindMed
ISS Dismissed 47% Stock Price Drop Following September 2022 Financing as In Line with “Sectoral Trends”, in a Baffling Lack of Critical Analysis and Seemingly in Opposition to the Factual...
FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board
02. Juni 2023 16:17 ET
|
Concerned Shareholders of Company MindMed
FCM Predicts That the Psychedelic Revolution Will Begin with the FDA’s Likely Groundbreaking Approval of the Drug MDMA, Which is Expected to Occur in the Second Half of 2024 Reiterates that MindMed...
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
30. Mai 2023 16:17 ET
|
Concerned Shareholders of Company MindMed
FCM Director Candidates, including Dr. Freeman, and Mr. Jake Freeman, Commit to Not Selling Any of Their MindMed Shares Until June 15, 2025 FCM and its Nominees Stand Behind Their Plan to Drive Value...
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
25. Mai 2023 16:57 ET
|
Concerned Shareholders of Company MindMed
MindMed has Slashed Allocation of Spending on Core Drugs While Executive Compensation has Soared to $51M MindMed Phase IIb Clinical Trial Delayed Greenleaf Health Study, Quoting FDA, Supports FCM’s...
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track
15. Mai 2023 08:24 ET
|
Concerned Shareholders of Company MindMed
FCM Believes MindMed Focused on Pursuing Misguided Clinical Path for MM-120 MindMed Executives, Advisors – Barrow, Karlin, and Liechti – Do Not Have Experience in Bringing Drugs to Market and...
FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Management’s Track Record of Shareholder Value Destruction
05. Mai 2023 08:08 ET
|
Concerned Shareholders of Company MindMed
MindMed Board has Presided over Botched Regulatory Strategies, Outsized Expenses, Soaring Executive Compensation, and Value Destructive Financings FCM’s Four Highly Qualified Director Nominees to...
FCM Nominates Exceptional Director Candidates to Restore MindMed’s Value
21. April 2023 08:22 ET
|
Concerned Shareholders of Company MindMed
Meaningful Change is Needed at MindMed After Years of Poor Performance FCM’s Candidates Have Decades of Relevant Industry Experience and are Laser Focused on Bringing MM-120 to Market FCM to Provide...
Activist Investor Informs MindMed of Financial Misstatements, Questions Internal Controls
14. November 2022 08:08 ET
|
Concerned Shareholders of Company MindMed
SHERIDAN, Wyo., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Today, FCM MM HOLDINGS, LLC (“FCM”) announces that it has sent a letter (the “Letter”) to the Board of Directors (the “Board”) of Mind Medicine...